- Histological diagnosis of GIST.
- Patients must have demonstrated either disease progression or intolerance to imatinib
mesylate, have non-mutant Stem Cell Factor Receptor gene (KIT) GIST, or cannot obtain
imatinib in their country.
- Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable
- Current treatment with another investigational agent.
- Prior sunitinib treatment.
- Prior therapy with known risk for cardiovascular complications.